A study of Kamerkar and colleagues reports that siRNA or shRNA drugs specific to oncogenic KrasG12D mutation were electroporated into human fibroblast CD47-enriched EVs and led to an inhibition of tumor proliferation in different in vivo models of pancreatic cancer, with a significant improvement in the survival rate [78,80,81]. The gene discussed is CD47; the disease is neoplasm.